- Home
- APLM vs NERV Comparison
APLM vs NERV Comparison
Compare APLM & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLM
- NERV
- Stock Information
- Founded
- APLM 2016
- NERV 2007
- Country
- APLM United States
- NERV United States
- Employees
- APLM N/A
- NERV N/A
- Industry
- APLM Blank Checks
- NERV Biotechnology: Pharmaceutical Preparations
- Sector
- APLM Finance
- NERV Health Care
- Exchange
- APLM Nasdaq
- NERV Nasdaq
- Market Cap
- APLM 15.6M
- NERV 18.3M
- IPO Year
- APLM N/A
- NERV 2014
- Fundamental
- Price
- APLM $7.89
- NERV $2.19
- Analyst Decision
- APLM Strong Buy
- NERV Hold
- Analyst Count
- APLM 2
- NERV 1
- Target Price
- APLM $425.00
- NERV $5.00
- AVG Volume (30 Days)
- APLM 106.0K
- NERV 14.3K
- Earning Date
- APLM 08-14-2024
- NERV 11-05-2024
- Dividend Yield
- APLM N/A
- NERV N/A
- EPS Growth
- APLM N/A
- NERV N/A
- EPS
- APLM N/A
- NERV N/A
- Revenue
- APLM $2,101,000.00
- NERV N/A
- Revenue This Year
- APLM N/A
- NERV N/A
- Revenue Next Year
- APLM N/A
- NERV N/A
- P/E Ratio
- APLM N/A
- NERV N/A
- Revenue Growth
- APLM 70.54
- NERV N/A
- 52 Week Low
- APLM $6.50
- NERV $2.06
- 52 Week High
- APLM $105.00
- NERV $13.49
- Technical
- Relative Strength Index (RSI)
- APLM 42.42
- NERV 45.26
- Support Level
- APLM $7.70
- NERV $2.08
- Resistance Level
- APLM $8.88
- NERV $2.32
- Average True Range (ATR)
- APLM 1.34
- NERV 0.13
- MACD
- APLM -0.04
- NERV 0.01
- Stochastic Oscillator
- APLM 24.77
- NERV 33.33
About APLM Apollomics Inc.
Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.